Presentations by Program

Search by Program

Efficacy and safety of sulbactam-durlobactam (SUL-DUR) therapy in patients with Acinetobacter baumannii-calcoaceticus complex (ABC) infections in the open label Part B of the ATTACK phase 3 trial

Khurram Rana, David Altarac, Robin Isaacs, Subasree Srinivasan, Sarah McLeod, Gabrielle Poirier, Andrew Shorr and Keith Kaye (ECCMID, 2022)

Characterization of Acinetobacter baumannii-calcoaceticus complex (ABC) pathogens isolated at baseline from patients enrolled in the ATTACK phase 3 trial

Alita Miller, Sarah McLeod, Daria Chabas, Gabrielle Poirier and David Altarac (ECCMID, 2022)

Efficacy and safety of sulbactam-durlobactam (SUL-DUR) versus colistin therapy in patients with Acinetobacter baumannii-calcoaceticus complex (ABC) infections: a global, randomized, active-controlled phase 3 trial (ATTACK)

David Altarac, Robin Isaacs, Subasree Srinivasan, Sarah McLeod, Khurram Rana, Gabrielle Poirier, Andrew Shorr and Keith Kaye (ECCMID, 2022)

Discovery of ETX0462, a novel non-β-lactam PBP inhibitor to treat Gram-negative infections, including MDR Pseudomonas aeruginosa

Thomas Durand-Reville (SCI-RSC, 2021)

In Vitro Activity of Sulbactam-Durlobactam against Recent Clinical Acinetobacter baumannii-calcoaceticus Complex Isolates

Sarah McLeod, Samir Moussa, Meredith Hackel and Alita Miller (ECCMID, 2021)

The β-lactamase inhibitor ETX1317 restores the activity of cefpodoxime against recent (2017 2019), geographically diverse drug resistant Enterobacterales isolates

Sarah McLeod, Michael Huband, Jennifer Thompson, John Mueller and Alita Miller (Microbe, 2021)

Evaluation of the Pharmacokinetics/pharmacodynamics (PK/PD) of the Novel Diazabicyclooctane (DBO) ETX0462 Against Pseudomonas aeruginosa Infections, Including MDR Strains

John O'Donnell, Angela Tanudra, April Chen, Dan Hines, Ruben Tommasi, Alita Miller, and Thomas Durand-Reville (Microbe, 2021)

ETX0462 is a Novel PBP Inhibitor with Potent Activity against Recent, Global, Gram-Negative Clinical Isolates

Sarah McLeod, Michael Huband, Jennifer Thompson, and Alita Miller (Microbe, 2021)

The Novel, Non-β-lactam PBP Inhibitor, ETX0462, Has Potent Activity Against Biothreat Pathogens In Vitro and In Vivo

Ruben Tommasi, Henry Heine, George Drusano, Jason Cummings, Richard Slayden, Thomas Durand-Reville, John O’Donnell, and Alita Miller (Microbe, 2021)

Sulbactam-Durlobactam MIC and Disk Diffusion Quality Control Ranges Using A CLSI M23-A4 Study Design

Sarah McLeod, Nicole Carter and Alita Miller (Microbe, 2021)